Despite the current undervaluation of PTVE, the negative growth outlook introduces a level of uncertainty and risk. Potential investors are advised to research further into the stock and consider the risks associated with negative future growth prospects.
The pessimism of the analyst cohort reflected in Pactiv Evergreen's declining revenue forecasts might impact its stocks. The current high P/S may not be sustainable due to these decreasing revenues.
Although Pactiv Evergreen's dividends were covered by free cash flow, its lack of profitability last year is worrisome. Dividend investors need to see evidence of sustained profitability to be positive.
RDK79
:
Only noted more downgraded than upgrades, lot of analysts late to the party. And a bunch of new ‘initiated’ by mostly unknown folks, but also a few surprised weren’t previously covered, like DIS.
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Pactiv Evergreen Stock Forum
• $Victoria's Secret (VSCO.US)$ +10.4% (In reaction to earnings)
• $Salesforce (CRM.US)$ +9.0% (In reaction to earnings)
• $Navigator (NVGS.US)$ +4.9% (names Mads Peter Zacho as CEO)
• $Weibo (WB.US)$ +4.7% (In reaction to earnings)
• $CAE Inc (CAE.US)$ +4.7% (In reaction to earnings)
• $Laredo Petroleum (LPI.US)$ +4% (authorized $200 mln share repurchase program)
• $Axsome Therapeutics (AXSM.US)$ +3.1% (Late-Breaking Presentations of P...
• $Genco Shipping & Trading (GNK.US)$ +4.7% (positive Barrons article)
• $NextDecade (NEXT.US)$ +4.7% (files for 4618226 share common stock offering by selling shareholder)
• $COMPASS Pathways (CMPS.US)$ +4.7% (COMPASS Pathways presents largest ever study of psilocybin therapy at American Psychiatric Association annual meeting)
• $Canoo (GOEV.US)$ +3.5% (files for 48043111 share common stock offering by selling shareholder)
• $American Axle & Mfg (AXL.US)$ +3.7% (pr...
• $CubeSmart (CUBE.US)$ : Raymond James Upgrades to Strong Buy from Outperform - PT $52 (from $60)
• $DTE Energy (DTE.US)$ : Credit Suisse Upgrades to Outperform from Neutral - PT $140 (from $142)
• $Consolidated Edison (ED.US)$ : Guggenheim Upgrades to Neutral from Sell - PT $94 (from $80)
• $Motorola Solutions (MSI.US)$ : Morgan Stanley Upgrades to Overweight from Equalweight - PT $240
• $Central North Airport (OMAB.US)$ : Morgan Stanley Upgrades to...
• $Boot Barn Holdings (BOOT.US)$ : Piper Sandler Upgrades to Overweight from Neutral - PT $121 (from $109)
• $EPAM Systems (EPAM.US)$ : BofA Securities Upgrades to Buy from Neutral - PT $400 (from $312)
• $Hersha Hospitality Trust (HT.US)$ : Stifel Upgrades to Buy from Hold - PT $14.50 (from $11)
• $Jounce Therapeutics (JNCE.US)$ : Raymond James Upgrades to Strong Buy from Outperform - PT $20 (from $15)
• $Pactiv Evergreen (PTVE.US)$ : RBC Capital Upgra...
• $CDW Corp (CDW.US)$: Stifel Upgrades to Buy from Hold - PT $210 (from $200)
• $Corteva (CTVA.US)$ : Loop Capital Upgrades to Buy from Hold - PT $69
• $CoreCivic, Inc. (CXW.US)$ : Wedbush Upgrades to Outperform from Neutral - PT $17 (from $10.85)
• $Delta Air Lines (DAL.US)$ : Barclays Upgrades to Overweight from Equalweight - PT $60 (from $42)
• $H.B. Fuller (FUL.US)$ : Baird Upgrades to Outperform from Neutral - PT $85
• $Huntington Ingalls Industries (HII.US)$ : Cowen U...
the float still so much left?
No comment yet